title: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus.
abstract: We examined the in vivo metabolic effects of vanadyl sulfate (VS) in non-insulin-dependent diabetes mellitus (NIDDM). Six NIDDM subjects treated with diet and/or sulfonylureas were examined at the end of three consecutive periods: placebo for 2 wk, VS (100 mg/d) for 3 wk, and placebo for 2 wk. Euglycemic hyperinsulinemic (30 mU/m2.min) clamps and oral glucose tolerance tests were performed at the end of each study period. Glycemic control at baseline was poor (fasting plasma glucose 210 +/- 19 mg/dl; HbA1c 9.6 +/- 0.6%) and improved after treatment (181 +/- 14 mg/dl [P < 0.05], 8.8 +/- 0.6%, [P < 0.002]); fasting and post-glucose tolerance test plasma insulin concentrations were unchanged. After VS, the glucose infusion rate during the clamp was increased (by approximately 88%, from 1.80 to 3.38 mg/kg.min, P < 0.0001). This improvement was due to both enhanced insulin-mediated stimulation of glucose uptake (rate of glucose disposal [Rd], +0.89 mg/kg.min) and increased inhibition of HGP (-0.74 mg/kg.min) (P < 0.0001 for both). Increased insulin-stimulated glycogen synthesis (+0.74 mg/kg.min, P < 0.0003) accounted for > 80% of the increased Rd after VS, and the improvement in insulin sensitivity was maintained after the second placebo period. The Km of skeletal muscle glycogen synthase was lowered by approximately 30% after VS treatment (P < 0.05). These results indicate that 3 wk of treatment with VS improves hepatic and peripheral insulin sensitivity in insulin-resistant NIDDM humans. These effects were sustained for up to 2 wk after discontinuation of VS.
authors.affiliation: Department of Medicine, Albert Einstein College of Medicine, New York 10461, USA.
authors.forename: N
authors.initials: N
authors.lastname: Cohen
authors.forename: M
authors.initials: M
authors.lastname: Halberstam
authors.forename: P
authors.initials: P
authors.lastname: Shlimovich
authors.forename: C J
authors.initials: CJ
authors.lastname: Chang
authors.forename: H
authors.initials: H
authors.lastname: Shamoon
authors.forename: L
authors.initials: L
authors.lastname: Rossetti
mesh_terms: D000284:Administration, Oral; D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005947:Glucose / Q000378:metabolism; D006006:Glycogen Synthase / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D007773:Lactates / Q000097:blood; D008099:Liver / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000201:enzymology; D006005:Phosphorylases / Q000378:metabolism; D017968:Vanadium Compounds / Q000008:administration & dosage*
chemical_list: D005230:Fatty Acids, Nonesterified; D007328:Insulin; D007773:Lactates; D017968:Vanadium Compounds; C034028:vanadyl sulfate; D006005:Phosphorylases; D006006:Glycogen Synthase; D005947:Glucose